CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 9 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: . METHODS: After conducting preclinical in vitro and in vivo studies, we evaluated the safety and pharmacodynamic effects of single escalating doses of NTLA-2001 in six patients with hereditary ATTR amyloidosis with polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per kilogram), within an ongoing phase 1 clinical study. RESULTS: after a single dose. Serial assessments of safety during the first 28 days after infusion in patients revealed few adverse events, and those that did occur were mild in grade. Dose-dependent pharmacodynamic effects were observed. At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram. CONCLUSIONS: . (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).
Overview
CoChat Summary
TL;DR
In six patients with hereditary ATTR amyloidosis with polyneuropathy, single intravenous doses of NTLA-2001, a CRISPR-Cas9 lipid nanoparticle therapy, produced dose-dependent reductions in serum TTR protein at day 28 and only mild adverse events. This interim phase 1 study provides early clinical proof of concept for in vivo CRISPR-Cas9 gene editing.
Key findings
- At day 28, mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the 0.1 mg/kg group and 87% (range, 80 to 96) in the 0.3 mg/kg group.
- Adverse events occurred in three of six patients and were all grade 1 (mild); no serious adverse events were observed. One patient had a grade 1 infusion-related reaction, and increased d-dimer levels in five of six patients returned to baseline by day 7.
- Preclinical studies showed durable TTR knockout after a single dose: in primary human hepatocytes, NTLA-2001 had EC50 0.05 to 0.15 nmol/L and EC90 0.17 to 0.67 nmol/L, with ≥93.7% TTR editing and ≥95% reduction in TTR protein production; in cynomolgus monkeys, a single dose of Cyn-LNP at 3 or 6 mg/kg produced maximum whole-liver gene editing of 73% and >94% reduction in serum TTR protein sustained over 12 months.
Methods
- Interim results from two initial dose groups of a two-part, global, phase 1, open-label, multicenter study: six patients with hereditary ATTR amyloidosis with polyneuropathy received a single intravenous dose of NTLA-2001 at 0.1 mg/kg or 0.3 mg/kg (three patients each) between November 2020 and April 2021.
- Key eligibility included age 18 to 80 years, polyneuropathy due to hATTR amyloidosis with or without cardiomyopathy, body weight 50 to 90 kg, and lack of access to approved ATTR treatments; prior TTR stabilizers were permitted after washout.
- Serum TTR protein was measured by validated enzyme-linked immunosorbent assay at baseline and weeks 1, 2, and 4; analyses were descriptive, comparing baseline with day 28 as mean percentage change and range. Preclinical work included primary human hepatocytes, transgenic mice, and cynomolgus monkeys.
Limitations
- The paper states that the study involves a very small number of patients with limited follow-up to date, and that continued serial measurements are planned to confirm durability. It also states that these are interim results from the first two dose groups in an ongoing dose-escalation study.
- Evident from the text: the clinical portion is open-label with no control group, uses descriptive analyses only, reports safety and pharmacodynamic effects through day 28, and does not report clinical outcomes such as disease progression, quality of life, or mortality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 1 Not valid · 5 Not checked · 56 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“TTR, which has a normal physiological role in vitamin A transport. 31”
What the sources say
- Supportedcites [31] 31. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail 2020; 22: 39-53. source
The Introduction states that TTR physiologically transports retinol-binding protein. The Therapeutic antisense oligonucleotides section links this function to vitamin A levels, supporting the paraphrase that TTR normally plays a role in vitamin A transport. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“but are limited by the requirement for long-term administration to maintain TTR knockdown.”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Trial Design and Regimens section reports patisiran infusions every three weeks for 18 months, and Pharmacodynamics reports sustained TTR reduction during that period. The paper does not establish that long-term administration is required to maintain knockdown after treatment stops, or that this limitation applies to current ATTR treatments generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [13] 13. Adams D, Polydefkis M, GonzálezDuarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an openlabel extension study. Lancet Neurol 2021; 20: 49-59. source
- Partly supportedcites [14] 14. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431-43. sourceExperimental — accuracy not yet measured
The Methods (Study Design and Treatment; page unavailable) report patisiran infusions every three weeks for 18 months, and the introductory passage describes its reduction of TTR protein. The paper does not establish that long-term administration is required to maintain TTR knockdown or characterize that requirement as a limitation of current ATTR treatments generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More extensive TTR knockdown is associated with greater improvement in neuropathic end points in patients with hATTR polyneuropathy. 12”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Primary End Point section reports a correlation between the degree of TTR reduction and change in mNIS+7, a composite neuropathy measure, at 18 months. The paper reports improvements in other end points, but our copy does not link the extent of knockdown to improvement across those end points. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“circulating TTR is produced almost entirely (>99%) within the liver, 2”
What the sources say
- Partly supportedcites [2] 2. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66: 2451-66. sourceExperimental — accuracy not yet measured
The section labeled “Diagnosis and Classification” says TTR is synthesized primarily in the liver, supporting the liver as its main source. It does not give the claimed >99% figure for circulating TTR. No page number is available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inotersen is associated with serious side effects, including glomerulonephritis and decreased platelet counts. 17”
What the sources say
- Supportedcites [17] 17. Gertz MA, Scheinberg M, Waddington-Cruz M, et al. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-medi- - ated amyloidosis. Expert Rev Clin Pharmacol 2019; 12: 701-11. source
The Safety and tolerability section (p. 9) reports decreased platelet counts and glomerulonephritis in patients receiving inotersen, including severe cases. The Regulatory affairs section (p. 9) states that the US approval carries a black box warning for increased risks of thrombocytopenia and glomerulonephritis. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
43 more claims · 1 with their cited sources checked
Create a free account to see all 69 claims and every source verdict.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“which has already lead to investigational new drugs in clinical trials (NCT04601051)”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Gillmore et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines (13, 14) that have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results (15–18).”
From Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease (2023) · cites this paper as [17]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationCRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Cited by
CAR T cells produced in vivo to treat cardiac injury
Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2022) · Science · doi:10.1126/science.abm0594 · Cited by 1,400
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
The role of lipid components in lipid nanoparticles for vaccines and gene therapy
Hald Albertsen, C., Kulkarni, J. A., Witzigmann, D., Lind, M., Petersson, K., & Simonsen, J. B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114416 · Cited by 1,185
CRISPR technology: A decade of genome editing is only the beginning
Wang, J. Y., & Doudna, J. A. (2023) · Science · doi:10.1126/science.add8643 · Cited by 1,049
“Notably, as mentioned above, LNPs are the delivery strategy used in the first systemic in vivo delivery of CRISPR in humans for the successful treatment of transthyretin amyloidosis (110).”
BackgroundInfluentialCAR T Cells Produced in vivo to Treat Cardiac Injury
Rurik, J. G., Tombácz, I., Yadegari, A., Fernández, P. O. M., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2023) · HAL · Cited by 926
The clinical progress of mRNA vaccines and immunotherapies
Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01294-2 · Cited by 823
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 771
Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719
CRISPR/Cas9 therapeutics: progress and prospects
Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P.-F., & Yu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01309-7 · Cited by 719
“Nonviral vectors have been a hot topic of research in recent years, where lipid nanoparticles have been used in the clinic for the delivery of CRISPR gene drugs.(31) Polymeric nanoparticles, biomimetic nanomaterials, and exosomes have also shown potential for the delivery of CRISPR systems in animal experiments.”
BackgroundInfluentialDilliard, S. A., & Siegwart, D. J. (2023) · Nature Reviews Materials · doi:10.1038/s41578-022-00529-7 · Cited by 671
Kittleson, M. M., Ruberg, F. L., Ambardekar, A. V., Brannagan, T. H., Cheng, R. K., Clarke, J. O., Dember, L. M., Frantz, J. G., Hershberger, R. E., Maurer, M. S., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.022 · Cited by 640
Off-target effects in CRISPR/Cas9 gene editing
Guo, C., Ma, X., Gao, F., & Guo, Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1143157 · Cited by 704
An ionizable lipid toolbox for RNA delivery
Han, X., Zhang, H., Butowska, K., Swingle, K. L., Alameh, M.-G., Weissman, D., & Mitchell, M. J. (2021) · Nature Communications · doi:10.1038/s41467-021-27493-0 · Cited by 628
Unlocking the promise of mRNA therapeutics
Rohner, E., Yang, R., Foo, K. S., Goedel, A., & Chien, K. R. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01491-z · Cited by 612
Past, present, and future of CRISPR genome editing technologies
Pacesa, M., Pelea, O., & Jinek, M. (2024) · Cell · doi:10.1016/j.cell.2024.01.042 · Cited by 609
“In a clinical trial, this approach demonstrated significant reduction of serum TTR levels, 287 the first successful case of a systemically delivered in vivo CRISPR gene therapy.”
BackgroundTherapeutic in vivo delivery of gene editing agents
Raguram, A., Banskota, S., & Liu, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.03.045 · Cited by 522
Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment
Liu, R., Luo, C., Pang, Z., Zhang, J., Ruan, S., Wu, M., Wang, L., Sun, T., Li, N., Han, L., et al. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.05.032 · Cited by 516
The landscape of mRNA nanomedicine
Huang, X., Kong, N., Zhang, X., Cao, Y., Langer, R., & Tao, W. (2022) · Nature Medicine · doi:10.1038/s41591-022-02061-1 · Cited by 511
The 60-year evolution of lipid nanoparticles for nucleic acid delivery
Cullis, P. R., & Felgner, P. L. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00977-6 · Cited by 503
“The clinical potential of LNP mRNA CRISPR gene editing of transthyretin to treat hATTR amyloidosis has also been demonstrated 155 .”
Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
Zong, Y., Lin, Y., Wei, T., & Cheng, Q. (2023) · Advanced Materials · doi:10.1002/adma.202303261 · Cited by 477
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
Deeks, S. G., Archin, N., Cannon, P., Collins, S., Jones, R. B., de Jong, M. A. W. P., Lambotte, O., Lamplough, R., Ndung’u, T., Sugarman, J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01590-5 · Cited by 377
Predicting transcriptional outcomes of novel multigene perturbations with GEARS
Roohani, Y., Huang, K., & Leskovec, J. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-01905-6 · Cited by 355
“…the predicted postperturbation gene expression for each of the 5,151 pairwise combinatorial perturbations, we constructed a genetic interaction map that could simultaneously represent five distinct types of genetic interactions: synergy, suppression, neomorphism, redundancy and epistasis.”
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
Dimitri, A., Herbst, F., & Fraietta, J. A. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01559-z · Cited by 352
“In these cases, inherited genetic diseases with known gene mutations can be corrected [1, 2].”
BackgroundCurrent approaches of nanomedicines in the market and various stage of clinical translation
Shan, X., Gong, X., Li, J., Wen, J., Li, Y., & Zhang, Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.025 · Cited by 335
Nanoparticles in the clinic: An update post COVID‐19 vaccines
Anselmo, A. C., & Mitragotri, S. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10246 · Cited by 337
Ray, K. K., Troquay, R. P. T., Visseren, F. L. J., Leiter, L. A., Scott Wright, R., Vikarunnessa, S., Talloczy, Z., Zang, X., Maheux, P., Lesogor, A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00353-9 · Cited by 328
Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components
Kazemian, P., Yu, S.-Y., Thomson, S. B., Birkenshaw, A., Leavitt, B. R., & Ross, C. J. D. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00916 · Cited by 329
Wan, T., Zhong, J., Pan, Q., Zhou, T., Ping, Y., & Liu, X. (2022) · Science Advances · doi:10.1126/sciadv.abp9435 · Cited by 299
“Because of its site-specific and multiplexing capability, CRISPR-Cas9–mediated somatic genome editing has shown great potential in treating various genetic disorders in animal models (2–4) and even in a recent phase 1 clinical trial for transthyretin amyloidosis (5).”
BackgroundPayload distribution and capacity of mRNA lipid nanoparticles
Li, S., Hu, Y., Li, A., Lin, J., Hsieh, K., Schneiderman, Z., Zhang, P., Zhu, Y., Qiu, C., Kokkoli, E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33157-4 · Cited by 295
“2c), three distinct populations were found: (1) TMR Cy5 coincidences accounting for 34% of all events detected, which were presumably lipophilic mRNA complexes that contain a substantial amount of helper lipid.”
BackgroundNanotechnology-based delivery of CRISPR/Cas9 for cancer treatment
Xu, X., Liu, C., Wang, Y., Koivisto, O., Zhou, J., Shu, Y., & Zhang, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113891 · Cited by 289
mRNA-based therapeutics: looking beyond COVID-19 vaccines
Parhiz, H., Atochina-Vasserman, E. N., & Weissman, D. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02444-3 · Cited by 279
Engineering Lipid Nanoparticles for Enhanced Intracellular Delivery of mRNA through Inhalation
Kim, J., Jozic, A., Lin, Y., Eygeris, Y., Bloom, E., Tan, X., Acosta, C., MacDonald, K. D., Welsher, K. D., & Sahay, G. (2022) · ACS Nano · doi:10.1021/acsnano.2c05647 · Cited by 273
Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges
Taha, E. A., Lee, J., & Hotta, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.013 · Cited by 259
In vivo human T cell engineering with enveloped delivery vehicles
Hamilton, J. R., Chen, E., Perez, B. S., Sandoval Espinoza, C. R., Kang, M. H., Trinidad, M., Ngo, W., & Doudna, J. A. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-02085-z · Cited by 256
“Although such capability would transform both clinical and research applications, current non-viral delivery is limited to cells treated ex vivo 4–6 , tissues targeted by local administration 7,8 or the liver because of its natural propensity for molecular uptake 8,9 .”
CRISPR technologies for genome, epigenome and transcriptome editing
Villiger, L., Joung, J., Koblan, L., Weissman, J., Abudayyeh, O. O., & Gootenberg, J. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00697-6 · Cited by 256
“…showing that a single dose of lipid nanoparticles (LNPs) encapsulating mRNA for Cas9 protein and sgRNA to knock out transthyretin in the liver could safely and durably reduce the concentration of toxic, misfolded transthyretin protein by 80–96% in patients with transthyretin amyloidosis 312 .”
Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid
Garcia-Pavia, P., aus dem Siepen, F., Donal, E., Lairez, O., van der Meer, P., Kristen, A. V., Mercuri, M. F., Michalon, A., Frost, R. J. A., Grimm, J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303765 · Cited by 248
Lee, R. G., Mazzola, A. M., Braun, M. C., Platt, C., Vafai, S. B., Kathiresan, S., Rohde, E., Bellinger, A. M., & Khera, A. V. (2023) · Circulation · doi:10.1161/circulationaha.122.062132 · Cited by 242
Thermal immuno-nanomedicine in cancer
Yang, Z., Gao, D., Zhao, J., Yang, G., Guo, M., Wang, Y., Ren, X., Kim, J. S., Jin, L., Tian, Z., et al. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00717-y · Cited by 242
Herrera-Barrera, M., Ryals, R. C., Gautam, M., Jozic, A., Landry, M., Korzun, T., Gupta, M., Acosta, C., Stoddard, J., Reynaga, R., et al. (2023) · Science Advances · doi:10.1126/sciadv.add4623 · Cited by 239
“For example, systemic administration of LNP mRNA encoding for RNA-guided Cas9 has led to knockdown of misfolded transthyretin (TTR) protein in six patients with amyloidosis, with over 90% reduction in TTR protein (33).”
BackgroundGene therapy clinical trials, where do we go? An overview
Arabi, F., Mansouri, V., & Ahmadbeigi, N. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113324 · Cited by 233
Strategies to reduce the risks of mRNA drug and vaccine toxicity
Bitounis, D., Jacquinet, E., Rogers, M. A., & Amiji, M. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00859-3 · Cited by 224
“Glucocorticoids and antihistaminic drugs were administered to patients with transthyretin amyloidosis before infusion of an LNP-enabled CRISPR– Cas9 gene editing therapy formulation to dampen possible systemic innate immune responses 191 .”
CRISPR-based genome editing through the lens of DNA repair
Nambiar, T. S., Baudrier, L., Billon, P., & Ciccia, A. (2022) · Molecular Cell · doi:10.1016/j.molcel.2021.12.026 · Cited by 208
Melamed, J. R., Yerneni, S. S., Arral, M. L., LoPresti, S. T., Chaudhary, N., Sehrawat, A., Muramatsu, H., Alameh, M.-G., Pardi, N., Weissman, D., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade1444 · Cited by 210
“R. Jain, J. P. Frederick, E. Y. Huang, K. E. Burke, D. M. Mauger, E. A. Andrianova, S. J. Farlow, S. Siddiqui, J. Pimentel, K. Cheung-Ong, K. M. McKinney, C. Köhrer, M. J. Moore, MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct.”
BackgroundResultInfluentialAssessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing
Tao, J., Bauer, D. E., & Chiarle, R. (2023) · Nature Communications · doi:10.1038/s41467-023-35886-6 · Cited by 207
RNA interference in the era of nucleic acid therapeutics
Jadhav, V., Vaishnaw, A., Fitzgerald, K., & Maier, M. A. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-02105-y · Cited by 207
CRISPR‐Cas Biochemistry and CRISPR‐Based Molecular Diagnostics
Weng, Z., You, Z., Yang, J., Mohammad, N., Lin, M., Wei, Q., Gao, X., & Zhang, Y. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202214987 · Cited by 203
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells
Tsuchida, C. A., Brandes, N., Bueno, R., Trinidad, M., Mazumder, T., Yu, B., Hwang, B., Chang, C., Liu, J., Sun, Y., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.041 · Cited by 209
Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications
Shi, Y., Shi, M., Wang, Y., & You, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02002-z · Cited by 206
Ottaviano, G., Georgiadis, C., Gkazi, S. A., Syed, F., Zhan, H., Etuk, A., Preece, R., Chu, J., Kubat, A., Adams, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq3010 · Cited by 199
“nanoparticles encapsulating Cas9 mRNA and sgRNA for knockout of transthyretin in amyloidosis has also been reported (22); this technique has also been used for the retinal disorder Leber’s amaurosis (23).”
MethodIn vivo somatic cell base editing and prime editing
Newby, G. A., & Liu, D. R. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.002 · Cited by 199
Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo
Ni, H., Hatit, M. Z. C., Zhao, K., Loughrey, D., Lokugamage, M. P., Peck, H. E., Cid, A. D., Muralidharan, A., Kim, Y., Santangelo, P. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32281-5 · Cited by 192
Han, J. P., Kim, M., Choi, B. S., Lee, J. H., Lee, G. S., Jeong, M., Lee, Y., Kim, E.-A., Oh, H.-K., Go, N., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj6901 · Cited by 191
“The results showed that LNP-CRISPR-Cas9 effectively inhibited pathogenic TTR expression by approximately 90% with only mild adverse events ( 37 ), demonstrating the translational feasibility of this approach.”
CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema
Longhurst, H. J., Lindsay, K., Petersen, R. S., Fijen, L. M., Gurugama, P., Maag, D., Butler, J. S., Shah, M. Y., Golden, A., Xu, Y., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309149 · Cited by 192
Self-citationHöijer, I., Emmanouilidou, A., Östlund, R., van Schendel, R., Bozorgpana, S., Tijsterman, M., Feuk, L., Gyllensten, U., den Hoed, M., & Ameur, A. (2022) · Nature Communications · doi:10.1038/s41467-022-28244-5 · Cited by 187
Enhancers in disease: molecular basis and emerging treatment strategies
Claringbould, A., & Zaugg, J. B. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.07.012 · Cited by 181
Combinatorial development of nebulized mRNA delivery formulations for the lungs
Jiang, A. Y., Witten, J., Raji, I. O., Eweje, F., MacIsaac, C., Meng, S., Oladimeji, F. A., Hu, Y., Manan, R. S., Langer, R., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-023-01548-3 · Cited by 185
“Other therapies, including vaccines 6,18–27 , protein replacement therapy 28 and gene editing 15 , are in various stages of investigation.”
In vivo editing of lung stem cells for durable gene correction in mice
Sun, Y., Chatterjee, S., Lian, X., Traylor, Z., Sattiraju, S. R., Xiao, Y., Dilliard, S. A., Sung, Y.-C., Kim, M., Lee, S. M., et al. (2024) · Science · doi:10.1126/science.adk9428 · Cited by 183
Nucleic acid drugs: recent progress and future perspectives
Sun, X., Setrerrahmane, S., Li, C., Hu, J., & Xu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02035-4 · Cited by 179
Advances in CRISPR therapeutics
Chavez, M., Chen, X., Finn, P. B., & Qi, L. S. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00636-2 · Cited by 176
Transthyretin cardiac amyloidosis
Porcari, A., Fontana, M., & Gillmore, J. D. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac119 · Cited by 175
“Only mild adverse events were observed in this early phase study.(68)”
BackgroundSelf-citationWang, Y.-S., Kumari, M., Chen, G.-H., Hong, M.-H., Yuan, J. P.-Y., Tsai, J.-L., & Wu, H.-C. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00977-5 · Cited by 173
“Although the clinical trial is still ongoing, the successful development of a product to this point supports the idea that in vivo mRNA-LNP-based genome editing may be a viable therapeutic strategy [60, 67].”
BackgroundCRISPR‐Cas‐based detection for food safety problems: Current status, challenges, and opportunities
Li, Y., Man, S., Ye, S., Liu, G., & Ma, L. (2022) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.13000 · Cited by 173
Loughrey, D., & Dahlman, J. E. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00601 · Cited by 173
Chemically Modified Platforms for Better RNA Therapeutics
Shi, Y., Zhen, X., Zhang, Y., Li, Y., Koo, S., Saiding, Q., Kong, N., Liu, G., Chen, W., & Tao, W. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00611 · Cited by 172
Designing and executing prime editing experiments in mammalian cells
Doman, J. L., Sousa, A. A., Randolph, P. B., Chen, P. J., & Liu, D. R. (2022) · Nature Protocols · doi:10.1038/s41596-022-00724-4 · Cited by 172
Drug delivery systems for CRISPR-based genome editors
Madigan, V., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 172
“TTR expression in patients following a 0.3 mg/kg RNA dose 16 , which was striking, as the same reductions in TTR expression in an NHP required a higher dose (see Related links).”
BackgroundMethodInfluentialRNA editing: Expanding the potential of RNA therapeutics
Booth, B. J., Nourreddine, S., Katrekar, D., Savva, Y., Bose, D., Long, T. J., Huss, D. J., & Mali, P. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.005 · Cited by 171
“Despite the potential and early clinical success of CRISPR-Cas DNA-editing technologies, 135 safety concerns persist.”
Rasul, M. F., Hussen, B. M., Salihi, A., Ismael, B. S., Jalal, P. J., Zanichelli, A., Jamali, E., Baniahmad, A., Ghafouri-Fard, S., Basiri, A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01487-4 · Cited by 171
Protein corona: Friend or foe? Co-opting serum proteins for nanoparticle delivery
Kim, W., Ly, N. K., He, Y., Li, Y., Yuan, Z., & Yeo, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114635 · Cited by 170
Kasiewicz, L. N., Biswas, S., Beach, A., Ren, H., Dutta, C., Mazzola, A. M., Rohde, E., Chadwick, A., Cheng, C., Garcia, S. P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37465-1 · Cited by 169
Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing
Qiu, M., Li, Y., Bloomer, H., & Xu, Q. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00500 · Cited by 167
RNA-targeting and gene editing therapies for transthyretin amyloidosis
Aimo, A., Castiglione, V., Rapezzi, C., Franzini, M., Panichella, G., Vergaro, G., Gillmore, J., Fontana, M., Passino, C., & Emdin, M. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00683-z · Cited by 163
Self-citationResearch Advances on the Stability of mRNA Vaccines
Cheng, F., Wang, Y., Bai, Y., Liang, Z., Mao, Q., Liu, D., Wu, X., & Xu, M. (2023) · Viruses · doi:10.3390/v15030668 · Cited by 162
“In the treatment of genetic diseases, clinical trials are ongoing for mRNA vaccines for cystic fibrosis [25], propionic acidemia [26], and transthyretin amyloidosis [27].”
BackgroundArtificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy
Witten, J. J., Raji, I. O., Manan, R. S., Beyer, E., Bartlett, S., Tang, Y., Ebadi, M., Lei, J., Nguyen, D., Oladimeji, F. A., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02490-y · Cited by 211
Shaath, H., Vishnubalaji, R., Elango, R., Kardousha, A., Islam, Z., Qureshi, R., Alam, T., Kolatkar, P. R., & Alajez, N. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.013 · Cited by 170
Enhanced T cell effector activity by targeting the Mediator kinase module
Freitas, K. A., Belk, J. A., Sotillo, E., Quinn, P. J., Ramello, M. C., Malipatlolla, M. B., Dániel, B., Sándor, K., Klysz, D. D., Bjelajac, J. R., et al. (2022) · Science · doi:10.1126/science.abn5647 · Cited by 163
“Technologies to inactivate genes in the context of ex vivo cell manufacturing and even in vivo gene editing (68), using a variety of approaches, including CRISPR-Cas9, Zinc finger nucleases, TALENs, or base editing, are increasingly available for emerging applications in human medicine (69), highlighting the potential…”
BackgroundDilliard, S. A., Sun, Y., Brown, M. O., Sung, Y., Chatterjee, S., Farbiak, L., Vaidya, A., Lian, X., Wang, X., Lemoff, A. S., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.058 · Cited by 167
Strategies for non-viral vectors targeting organs beyond the liver
Kim, J., Eygeris, Y., Ryals, R. C., Jozić, A., & Sahay, G. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01563-4 · Cited by 173
“The utilization of NPs expands beyond vaccines 3 , and we witness persistent endeavours to overcome liver tropism.”
The state of cell and gene therapy in 2023
Chancellor, D., Barrett, D., Nguyen-Jatkoe, L., Millington, S., & Eckhardt, F. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.001 · Cited by 155
Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy
Swingle, K. L., Safford, H. C., Geisler, H. C., Hamilton, A. G., Thatte, A. S., Billingsley, M. M., Joseph, R. A., Mrksich, K., Padilla, M. S., Ghalsasi, A. A., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c12893 · Cited by 145
Li, F., Song, N., Dong, Y., Li, S., Li, L., Liu, Y., Li, Z., & Yang, D. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202116569 · Cited by 156
Increasing life expectancy in cystic fibrosis: Advances and challenges
McBennett, K., Davis, P. B., & Konstan, M. W. (2021) · Pediatric Pulmonology · doi:10.1002/ppul.25733 · Cited by 183
Philipp, J., Dabkowska, A. P., Reiser, A., Frank, K., Krzysztoń, R., Brummer, C., Nickel, B. A., Blanchet, C. E., Sudarsan, A., Ibrahim, M., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2310491120 · Cited by 172
Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis
Ando, Y., Adams, D., Benson, M., Berk, J., Planté-Bordeneuve, V., Coelho, T., Conceição, I., Ericzon, B., Obici, L., Rapezzi, C., et al. (2022) · Amyloid: Journal of Protein Folding Disorders · doi:10.1080/13506129.2022.2052838 · Cited by 123
“Remarkably, the possibility to knockout the TTR gene using the CRISPR-Cas9 technology, as recently reported, gives hope to cure this disease [34].”
Lipid Nanoparticles Optimized for Targeting and Release of Nucleic Acid
Jia, Y., Wang, X., Li, L., Li, F., Zhang, J., & Liang, X. (2023) · Advanced Materials · doi:10.1002/adma.202305300 · Cited by 171
Non-viral delivery of the CRISPR/Cas system: DNA versus RNA versus RNP
Lin, Y., Wagner, E., & Lächelt, U. (2022) · Biomaterials Science · doi:10.1039/d1bm01658j · Cited by 154
Xue, L., Hamilton, A. G., Zhao, G., Xiao, Z., El-Mayta, R. D., Han, X., Gong, N., Xiong, X., Xu, J., Figueroa‐Espada, C. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45422-9 · Cited by 167
Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
Ewaisha, R., & Anderson, K. S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1138596 · Cited by 163
“The first clinical trial involving systemic delivery of CRISPR components used SpCas9 and a sgRNA targeting TTR (NTLA-2000) to reduce the production of misfolded transthyretin protein in hereditary transthyretin amyloidosis (Gillmore et al., 2021).”
BackgroundMethodInfluentialRNA‐based medicine: from molecular mechanisms to therapy
Sparmann, A., & Vogel, J. (2023) · The EMBO Journal · doi:10.15252/embj.2023114760 · Cited by 156
“Notable examples for successful in vivo delivery of CRISPR-based therapeutics are clinical trials to treat the neurodegenerative disease hATTR (Gillmore et al , 2021) and the treatment of Leber congenital amaurosis 10 (LCA10), a type of congenital blindness (Maeder et al , 2019).”
Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids
Mendonça, M. C. P., Kont, A., Kowalski, P. S., & O’Driscoll, C. M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103505 · Cited by 150
Hino, T., Omura, S. N., Nakagawa, R., Togashi, T., Takeda, S. N., Hiramoto, T., Tasaka, S., Hirano, H., Tokuyama, T., Uosaki, H., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.031 · Cited by 136
“27 We injected 7-week-old mice with 3 3 10 11 or 1 3 10 12 vg of the hepatotropic AAV serotype 8 and evaluated the expression level of plasma transthyretin.”
MethodCRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy
Fontana, M., Solomon, S. D., Kachadourian, J., Walsh, L., Rocha, R., Lebwohl, D., Smith, D. K., Täubel, J., Gane, E. J., Pilebro, B., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2412309 · Cited by 153
Self-citationLipid carriers for mRNA delivery
Zhang, W., Jiang, Y., He, Y., Boucetta, H., Wu, J., Chen, Z., & He, W. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.026 · Cited by 141
“Although degradable ionizable lipids can alleviate the unwanted effects, long-term treatment still requires premedication with glucocorticoids and antihistamines 261 .”
Chaudhary, N., Kasiewicz, L. N., Newby, A. N., Arral, M. L., Yerneni, S. S., Melamed, J. R., LoPresti, S. T., Fein, K. C., Petersen, D. M. S., Kumar, S., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01256-w · Cited by 178
“…vaccines has bolstered LNPs as the preferred delivery sys-tem for prophylactic vaccines, and next-generation RNA platforms (for example, replicons 4,5 , circular RNA 6,7 and base editors 8 ) are under development for protein replacement 9 , gene editing 10 , immunotherapies 11 and cancer 12,13 .”
Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies
Wei, P.-S., Thota, N., John, G., Chang, E., Lee, S., Wang, Y., Ma, Z., Tsai, Y.-H., & Mei, K. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.030 · Cited by 149
“Ester conjugated cleavable tail design has dominated the chemical space of ionizable inverse micellular lipids, e.g., A9 [124], IR-117-17 (A10-Lin) [22], RCB-4– 8 [21], PL-1 [125], L101 [126], RM-133-3 [127], LP-01 [128,129], C24, 3-”
Khoshandam, M., Soltaninejad, H., Mousazadeh, M., Hamidieh, A. A., & Hosseinkhani, S. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.027 · Cited by 152
“Initially reported with CRISPR-based in vivo gene editing, this innovation was linked to transthyretin amyloidosis, or ATTR amyloidosis, which resulted from the accumulation of misfolded transthyretin (TTR) protein in different organs and tissues.(37) ATTR amyloidosis is a monogenic infection and almost all TTR protei…”
BackgroundClinical delivery of circular RNA: Lessons learned from RNA drug development
Young, T. L., Wang, K. C., Varley, A., & Li, B. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114826 · Cited by 133
Branched chemically modified poly(A) tails enhance the translation capacity of mRNA
Chen, H., Liu, D., Guo, J., Aditham, A. J., Zhou, Y., Tian, J., Luo, S., Ren, J., Hsu, A., Huang, J., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02174-7 · Cited by 150
Human genetic diversity alters off-target outcomes of therapeutic gene editing
Cancellieri, S., Zeng, J., Lin, L. Y., Tognon, M., Nguyen, M. A., Lin, J., Bombieri, N., Maitland, S. A., Ciuculescu, M.-F., Katta, V., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01257-y · Cited by 131
Metadata
- Authors
- Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., Kyratsous, C. A., Zambrowicz, B., Soltys, R., Gutstein, D. E., Leonard, J., Sepp-Lorenzino, L., & Lebwohl, D.
- Affiliations
- University of Auckland (NZ)
- From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George’s University of London (J.T.) — both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) — all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 493-502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177445623
- Cited by
- 1,801
- References
- 35
- Citations by year
- 2026: 349 · 2025: 332 · 2024: 368 · 2023: 336 · 2022: 328 · 2021: 84
- FWCI
- 228.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Intellia Therapeutics
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- transthyretin amyloidosis, hereditary ATTR amyloidosis, CRISPR/Cas9 genome editing, in vivo gene therapy, prealbumin, polyneuropathy, single ascending dose, pharmacodynamics, safety
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Female, Humans, Infusions, Intravenous, Liposomes, Male, Middle Aged, Prealbumin, RNA, Messenger, RNA, Guide, Kinetoplastida, Gene Transfer Techniques, Amyloid Neuropathies, Familial, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



